New hope for tough leukemia? early trial combines three drugs
NCT ID NCT07320235
First seen Jan 11, 2026 · Last updated Jun 19, 2026 · Updated 33 times
Summary
This early-phase trial is testing a new drug called imetelstat, combined with two standard chemotherapy drugs (azacitidine and venetoclax), in adults whose acute myeloid leukemia has returned or not responded to prior treatment. The study has two parts: first, finding a safe dose of imetelstat with azacitidine, then adding venetoclax to see the best dose and early signs of effectiveness. Up to 36 participants will be enrolled at one hospital.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RELAPSED ACUTE MYELOID LEUKEMIA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Icahn School of Medicine at Mount Sinai
RECRUITINGNew York, New York, 10029, United States
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact Phone: •••-•••-•••• Email: •••••@•••••
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
imetelstat (a drug that targets telomerase), azacitidine, and venetoclax
What this could lead to
If successful, this could point toward a new treatment option for people with relapsed acute myeloid leukemia who have run out of standard therapies.
What could go wrong
This is a very early Phase 1 trial with only 36 participants, so it is primarily testing safety and dosing. It may not show strong anti-cancer effects, and side effects could be significant.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.